John Allan, MD
Assistant Professor of Medicine
Division of Hematology and Medical Oncology 
Weill Cornell Medicine
New York, New York

Dr. Allan is an Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine in New York, New York. He received a Bachelor of Science in both Biochemistry and Finance at the University of Missouri in Columbia, Missouri, and completed his medical degree at Saint Louis University School of Medicine in St. Louis, Missouri. Seeking an internal medicine residency program with a particular strength in oncology, Dr. Allan moved to New York to train at New York–Presbyterian Hospital, Weill Cornell Medical Campus, where he also completed his hematology and medical oncology fellowship.

Dr. Allan joined the lymphoma faculty in the Division of Hematology and Oncology upon completion of his training, and he is a member of the Chronic Lymphocytic Leukemia (CLL) Research Center at Weill Cornell Medicine.  He treats all lymphoid malignancies and has particular interest in improving therapies for patients with CLL and Richter’s Syndrome, which is the focus of his research.
 

Amy L Goodrich, RN, MSN, CRNP-AC
Research Associate
The Johns Hopkins School of Medicine
Nurse Practitioner
The Sidney Kimmel Cancer Center at Johns Hopkins 
Baltimore, Maryland

Amy Goodrich, RN, MSN, CRNP, Research Associate, is a Nurse Practitioner in the Hematologic Malignancies Program and Research Nursing Manager at The Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland. Ms. Goodrich manages patients with various types of hematologic malignancies, concentrating on the lymphomas. She also manages the Cancer Center’s research nurses and is extremely involved in research operations.

Ms. Goodrich earned her Master’s Degree in 2000 as an Acute Care Nurse Practitioner from the Johns Hopkins University and her undergraduate nursing degree from the University of Pittsburgh.

Barbara Rogers, CRNP, MN, AOCN, ANP-BC
Adult Hematology-Oncology Nurse Practitioner
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Ms. Rogers is a Nurse Practitioner at Fox Chase Cancer Center in Philadelphia, Pennsylvania. She obtained her BSN from Trenton State College, her MN from UCLA and her post-master’s NP certificate from Temple University. Ms. Rogers has over 40 years of oncology experience with most of that time focused on the care of patients with hematologic malignancies. She has authored many peer-reviewed journal articles and book chapters, as well as given many presentations related to the care of patients with hematologic malignancies and symptom management. Ms. Rogers has held leadership positions in multiple organizations such as serving on the ONS Board of Directors, Chair of the ONS Nominating Committee, and Chair of the Advanced Practice Test Development Committee of the Oncology Nursing Certification Corporation. Currently, she is a member of the Education Committee of the Advanced Practitioner Society for Hematology and Oncology (APSHO).

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planner:  
Vanessa Carranza, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
 
Authors/Presenters:
John Allan, MD—has disclosed that he is a consultant for Abbvie, AstraZeneca, BeiGene, Genentech, Janssen, and PCYC. He receives grant/research support from Celgene, Genentech, Janssen, and TG Therapeutics. He is on the speakers' bureau for Abbvie, BeiGene, and PCYC/Janssen.   

Amy L Goodrich, RN, MSN, CRNP-AC—has disclosed that she is a consultant for Gilead, Mylan, and Sandoz.

Barbara Rogers, CRNP, MN, AOCN, ANP-BC—has disclosed that she is a consultant for Cardinal Health, Genentech, and Merck. She is on the speakers' bureau for AbbVie, Genentech, and Seattle Genetics.

Reviewers:
Amy L. Goodrich, RN, MSN, CRNP-AC—has disclosed that she is a consultant for Gilead, Mylan, and Sandoz.

Barbara Rogers, CRNP, MN, AOCN, ANP-BC—has disclosed that she is a consultant for Cardinal Health, Genentech, and Merck. She is on the speakers' bureau for Abbvie, AstraZeneca, Coherus, and Genentech.

Bryan C. Taylor, PharmD - has no relevant financial relationships to disclose in relation to the content of this activity.